Showing results (61-70 of 93) with videos related to
Sort By:
Pageof 10
Neoplasia (New York, N.Y.)|April 10, 2022
Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cellsSara Haddock, Tyler J Alban, Şevin Turcan, et al.Immunity|March 23, 2021
Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancerMaria Tello-Lafoz, Katja Srpan, Elisa E Sanchez, et al.The Journal of Experimental Medicine|November 23, 2021
An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancyBassem D Khalil, Roberto Sanchez, Tasrina Rahman, et al.Nature Cancer|January 7, 2022
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGFβ2Ana Rita Nobre, Emma Risson, Deepak K Singh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2022
Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal MetastasesN Ari Wijetunga, Alexander G Goglia, Nils Weinhold, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2023
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer CellsVeronica Calvo, Wei Zheng, Anna Adam-Artigues, et al.Nature Cell Biology|January 24, 2017
Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironmentsGeorg Fluegen, Alvaro Avivar-Valderas, Yarong Wang, et al.Trends in Cancer|December 3, 2025
The evolving landscape of brain metastasis: volume IIManuel Valiente, Carey Anders, Adrienne Boire, et al.Journal of Neuro-Oncology|June 8, 2020
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancerRachna Malani, Martin Fleisher, Priya Kumthekar, et al.NPJ Breast Cancer|March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumabEmanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.Pageof 10